How This Evidence Evolved
MS Treatment Strategy
Flipping the treatment pyramid
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Clinical relapse at 1 year: 68% reduction (P<0.001); disability progression at 2 years: 42% reduction
Annualized relapse rate over 96 weeks: ocrelizumab 0.16 vs interferon beta-1a 0.29 in both trials (46% lower in I; 47% lower in II; p<0.001 each)
12-week-confirmed disability progression: ocrelizumab 32.9% vs placebo 39.3% (HR 0.76, 95% CI 0.59–0.98; P=0.03)
EDSS change at 5 years: early intensive 0.3 vs escalation 1.2 (adjusted beta -0.85; 95% CI -1.38 to -0.32; p=0.002)
Treatment-strategy evidence: escalation vs early highly effective therapy (narrative review)
Follow-up studies, subgroup analyses, and real-world validation
Annualized relapse rates: ofatumumab 0.11 vs teriflunomide 0.22 (trial 1), 0.10 vs 0.25 (trial 2); serious infections 2.5% vs 1.8% (median follow-up 1.6 years).
At 96 weeks, annualized relapse rates: cumulative cladribine 3.5/5.25 mg/kg 0.14/0.15 vs placebo 0.33; lymphocytopenia 21.6%/31.5% vs 1.8%.
Current standard of care and ongoing research directions
Landmark Trials in This Story
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Clinical relapse at 1 year: 68% reduction (P<0.001); disability progression at 2 years: 42% reduction
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Annualized relapse rate over 96 weeks: ocrelizumab 0.16 vs interferon beta-1a 0.29 in both trials (46% lower in I; 47% lower in II; p<0.001 each)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
12-week-confirmed disability progression: ocrelizumab 32.9% vs placebo 39.3% (HR 0.76, 95% CI 0.59–0.98; P=0.03)
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
EDSS change at 5 years: early intensive 0.3 vs escalation 1.2 (adjusted beta -0.85; 95% CI -1.38 to -0.32; p=0.002)
The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis.
Treatment-strategy evidence: escalation vs early highly effective therapy (narrative review)
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Annualized relapse rates: ofatumumab 0.11 vs teriflunomide 0.22 (trial 1), 0.10 vs 0.25 (trial 2); serious infections 2.5% vs 1.8% (median follow-up 1.6 years).
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
At 96 weeks, annualized relapse rates: cumulative cladribine 3.5/5.25 mg/kg 0.14/0.15 vs placebo 0.33; lymphocytopenia 21.6%/31.5% vs 1.8%.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.